In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species

Diagnostic Microbiology and Infectious Disease

Volumn 31, Issue 2, 1998, Pages 343-347

  Zhanel, George G ^a,b   Karlowsky, James A ^a,b   Hoban, Daryl J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; CLINAFLOXACIN; GENTAMICIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; STREPTOMYCIN; TEICOPLANIN; TROVAFLOXACIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CANADA; ENTEROCOCCUS; HEALTH SURVEY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CANADA; CIPROFLOXACIN; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; OFLOXACIN; QUINOLINES; QUINOLONES; VANCOMYCIN;

EID: 0031802320     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00019-4     Document Type: Article

References (10)

1. Cohen M.A., Huband M.D., Gage J.W., Yoder S.L., Roland G.E., Gracheck S.J. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother. 40:1997;205-211.
2. Coque T.M., Singh K.V., Murray B.E. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci. J Antimicrob Chemother. 37:1996;1011-1016.
3. Cormican M.G., Jones R.N. In-vitro activity of trovafloxacin (CP99,219) tested by two methods against 150 vancomycin-resistant enterococcal isolates. J Antimicrob Chemother. 37:1996;847-849.
4. Devriese L.A., Pot B., Kersters K., Lauwers S., Haesebrouck F. Acidification of methyl-α-D-glucopyranoside: a useful test to differentiate Enterococcus casseliflavus and Enterococcus gallinarum from Enterococcus faecium species group and from Enterococcus faecalis. J Clin Microbiol. 34:1996;2607-2608.
5. Leclercq R., Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis. 24:1997;545-556.
6. Methods for Dilution Antimicrobial Susceptibility Testing for Bacteria That Grow Aerobically Approved Standard M7-A4 . 1997;NCCLS, Villanova, PA.
7. Ofner-Agostini M.E., Conly J., Paton S., Kureishi A., Nicolle L., Mulvey M., Johson W., Johnston L. Vancomycin-resistant enterococci (VRE) in Canada results of the Canadian nosocomial infection surveillance program 1996 VRE point prevalence surveillance project . Can J Infect Dis. 8:1997;73-78.
8. Segal-Maurer S., Urban C., Rahal J.J. Current perspectives on multidrug-resistant bacteria. Infect Dis Clin North Am. 10:1996;939-957.
9. Williams A.M., Rodrigues U.M., Collins M.D. Intrageneric relationships of enterococci as determined by reverse transcriptase sequencing of small-subunit rRNA. Res Microbiol. 142:1991;67-74.
10. Woodcock J.M., Andrews J.M., Boswell F.J., Brenwald N.P., Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother. 41:1997;101-106.